Completed
A Prospective Randomized Trial of Structured Treatment Interruption (STI) Followed by the Initiation of a New Antiretroviral Regimen vs. Immediate Switching to a New Antiretroviral Regimen in HIV-Infected Patients Experiencing Virologic Failure on HAART
Learn MoreCompleted
An International, Open-Label, Randomized, Multicentre Study to Evaluate the Antiviral Effect, Tolerability, Safety and Pharmacokinetics of Fortovase (saquinavir SGC) and Norvir (ritonavir) QD vs. Crixivan (indinavir) and Norvir (ritonavir) BID in HIV-Infected Patients
Learn MoreCompleted
An Open-Label, Comparative Study to Evaluate the Antiviral Efficacy and Safety of Nevirapine and Efavirenz or Both Drugs Combined in Combination with d4T and 3TC. (The 2NN or Double Non-Nucleoside Study): Trial results
Learn MoreCompleted
A Pilot Study Comparing Two Modalities of Multiple Drug Rescue Therapy (MDRT) among Pre-Treated, HIV-1 Infected Individuals - Full versus Sensitivity-Based MDRT Protocol: Trial results
Learn MoreCompleted
A Randomized Placebo-Controlled Study of the Safety and Efficacy of Efavirenz (DMP), Didanosine and Stavudine in Combination with or without Hydroxyurea in Antiretroviral-Naïve or -Experienced, HIV-Infected Patients:
Learn MoreCompleted
A Comparison of a Four-drug Regimen Comprised of 141W94, Abacavir (1592U89), and Combivir with a Three-drug Regimen Comprised of Nelfinavir and Combivir in Antiretroviral-Naïve, HIV-Infected Subjects. (Protocol 528/270 [NZTA4002])
Learn MoreCompleted
A Comparative Study of the Antiviral Effect of a Two or Three Times Daily Triple-Drug Regimen (Indinavir, Nelfinavir or Saquinavir [SGC], Lamivudine plus Zidovudine or Stavudine) against a Once Daily Regimen including Adefovir, Didanosine, Lamivudine and Nevirapine: Trial results
Learn MoreCompleted
A Pharmacokinetic Assessment of Intermittent Rifabutin Dosing Regimens in the Setting of Protease Inhibitor Therapy with a Combination of Ritonavir and Saquinavir in HIV-Infected Patients: Trial results
Learn MoreCompleted
A Phase III Trial to Compare the Safety and Antiviral Efficacy of 141W94 with Indinavir in Combination with Standard Nucleoside Reverse Transcriptase Inhibitor (NRTI) Therapy in NRTI-Experienced, Protease Inhibitor (PI)-Naïve, HIV-1 Infected Patients. (Protocol PROA/B3006 [569/050]): Trial results
Learn More
CTN Trials have been approved by the Community Advisory Committee of the Canadian HIV Trials Network and the Network’s Scientific Review Committee, or other national peer-review panels such as those at the Canadian Institutes of Health Research and the U.S. National Institutes of Health. CTNPT studies are small-scale investigations designed to determine the feasibility of research concepts, and do not all go through the regular CTN clinical trial review process. For information on the benefits and risks of participating in HIV clinical trials, call CATIE toll-free at 1-800-263-1638.
